Details for New Drug Application (NDA): 214804
✉ Email this page to a colleague
NDA 214804 describes HEPARIN SODIUM, which is a drug marketed by Abraxis Pharm, Aspen Global Inc, B Braun Medical, Be Pharms, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Dr Reddys, Emerge Bioscience, Epic Pharma Llc, Fresenius Kabi Usa, Gland, Hikma, Hospira, Hospira Inc, Lilly, Luitpold, Parke Davis, Pfizer, Pharm Spec, Pharmacia And Upjohn, Pharmobedient, Plano Pharms, Sagent Pharms, Shenzhen Techdow, Smith And Nephew, Solopak, Watson Labs Inc, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny, and is included in sixty-nine NDAs. It is available from twenty-two suppliers. Additional details are available on the HEPARIN SODIUM profile page.
The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
Summary for 214804
| Tradename: | HEPARIN SODIUM |
| Applicant: | Be Pharms |
| Ingredient: | heparin sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 214804
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 214804 | ANDA | BE Pharmaceuticals Inc. | 71839-117 | 71839-117-25 | 25 VIAL, SINGLE-DOSE in 1 CARTON (71839-117-25) / 2 mL in 1 VIAL, SINGLE-DOSE (71839-117-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 1,000 UNITS/ML | ||||
| Approval Date: | Dec 29, 2020 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
